This review summarizes the pharmacological mechanisms of first-generation calcium channel antagonists at the L-type voltage-gated calcium channel.
Answers are grounded in this paper and cite their sources.
Clarifies CCB binding at L-type channels; leaves open clinical relevance of regulatory dynamics.
The calcium channel antagonists are a chemically heterogeneous group of agents that includes verapamil, nifedipine, and diltiazem as first-generation agents. They owe their effectiveness to interactions at specific sites associated with a major protein of the L class of voltage-gated channel. The calcium channel may be viewed as a pharmacologic receptor, with specific sites for activator and antagonist ligands that are linked to the functional machinery of the channel. These sites are subject to homologous and heterologous regulation and a number of disease states--both experimental and clinical--alter their expression. The selective actions of these agents are reviewed from several perspectives, particularly that of voltage-dependent interactions that distinguish between cells according to membrane potential and other factors.
No takes yet. Share an insight, caveat, or question.
David J. Triggle (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: